CAARUD: client profiles and practices in 2008


CAARUD: client profiles and practices in 2008

Tendances n° 74, OFDT, 9 p.
December 2010

The status of CAARUD (Support Centres for the Reduction of Drug-related Harms) has been accessible since 2006 to structures (e.g., "drop-in", needle exchange programmes, street teams and mediation teams) that carry out drug-related harm reduction missions.
French CAARUDs mainly admit drug users who, although they can be followed up by healthcare system services (whether or not specialised in addictology), tend to have, on average, more uncontrolled addiction than users in general and live in more unstable social situations.
In order to acquire monitoring indicators for the characteristics of treated drug users and help improve the responses of professionals and authorities to the changing needs of this population, a biennial national survey of treated drug users was announced by the National Health Directorate (DGS). The survey is called "ENa-CAARUD".
This issue of Tendances presents the main results of the second edition of this survey, which was conducted in 2008.

Authors : Agnès Cadet-Taïrou, Anaëlle Coquelin, Abdalla Toufik

Download the PDF file (490 Ko)










Drugs in Europe

2021 EMCDDA European Drug Report

How is the COVID-19 pandemic affecting drug use, supply and services?
Drug use and harms
What are the health costs of drug use in Europe today?
Drug markets
What do the latest data tell us about drug production and trafficking trends?

These and other questions are explored in the 2021 European Drug Report, our annual overview of the drug situation in Europe.

  Statistical Bulletin 2021

The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format..

The European Union and the drug phenomenon

miniFAQDrugsEurope.jpgThe European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.